NCT07724886Recruiting
Role of ERBT Plus Intravesical BCG in Intermediate-Risk or High-Risk NMBC
A Randomised Trial Investigating the Role of Transurethral En Bloc Resection of Bladder Tumour Plus Intravesical Bacillus Calmette-Guerin Therapy, in Patients With Intermediate-Risk or High-Risk Non-Muscle-Invasive Bladder Cancer
Source: ClinicalTrials.gov · Last updated 27 Oct 2026
Brief summary (registry, in English)
This is a prospective, multi-centre randomised trial comparing between cTURBT plus 1-year BCG therapy, and ERBT plus 1-year BCG therapy, in patients with intermediate-risk or high-risk NMIBC.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 732 (estimated)
- First submitted
- 22 Apr 2026
- Start date
- 19 Oct 2026
- Primary completion date
- 31 Dec 2029
- Lead sponsor
- Chinese University of Hong Kong
- Diseases
- Bladder cancer
- NCT number
- NCT07724886
What you commit to
- Study type: Interventional
- Planned participants: 732
- From 19 Oct 2026 to the primary completion date, 31 Dec 2029
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- EAU low-risk NIMBC as intravesical BCG therapy should not be offered (5)
- Any prior use of intravesical BCG therapy
- Presence or prior history of upper urinary tract malignancy
- Presence of clinically significant cardiovascular disease (History of acute myocardial infarction, presence of uncontrolled angina within 3 months before screening, New York Heart Association Class III or IV congestive heart failure, presence of ventricular arrhythmias, or presence of second-degree or third-degree heart block) (16)
Other illness
- Presence of GOLD Stage III or IV chronic obstructive pulmonary disease
- History of bleeding disorder or use of anti-coagulants
- Presence of other active malignancy
Other
- EAU very high-risk NMIBC as upfront radical cystectomy should be offered (5)
- ECOG performance status ≥ 2 (Ambulatory and capable of all self-care but unable to carry our any work activities) (18)
- Pregnancy
Who the study is looking for
- Age 18 years or above
- Fulfil any one of the following three criteria:
- Recurrent bladder tumour
- Multiple bladder tumours
- Any bladder tumour size of \>1cm
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Prince of Wales Hospital Coordinator of this site? Confirm its status | Hong Kong | Hong Kong SAR China | Recruiting |
| North District Hospital Coordinator of this site? Confirm its status | Sheung Shui | Hong Kong SAR China | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.